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Abstract
Background: The impact on informal caregivers of caring for people with Alzheimer's disease (AD) dementia can be
substantial, but it remains unclear which measures(s) best assess such impact. Our objective was to use data from the
GERAS study to assess the ability of the EuroQol 5-dimension questionnaire (EQ-5D) to measure the impact on
caregivers of caring for people with AD dementia and to examine correlations between EQ-5D and caregiver burden.
Methods: GERAS was a prospective, non-interventional cohort study in community-dwelling patients with AD
dementia and their informal caregivers. The EQ-5D and Zarit Burden Interview (ZBI) were used to measure health-
related quality of life and caregiver burden, respectively. Resource-use data collected included caregiver time spent
with the patient on activities of daily living (ADL). Spearman correlations were computed between EQ-5D scores, ZBI
scores, and time spent on instrumental ADL (T-IADL) at baseline, 18 months, and for 18-month change scores. T-IADL
and ZBI change scores were summarized by EQ-5D domain change category (better/stable/worse).
Results: At baseline, 1495 caregivers had mean EQ-5D index scores of 0.86, 0.85, and 0.82, and ZBI total scores of 24.6,
29.4, and 34.1 for patients with mild, moderate, and moderately severe/severe AD dementia, respectively. Change in
T-IADL showed a stronger correlation with change in ZBI (0.12; P < 0.001) than with change in EQ-5D index score (0.02;
P = 0.546) although both correlations were very weak. Worsening within EQ-5D domains was associated with increases
in ZBI scores, although 68%–90% of caregivers remained stable within each EQ-5D domain. There was no clear pattern
for change in T-IADL by change in EQ-5D domain.
Conclusions: EQ-5D may not be the optimum measure of the impact of caring for people with AD dementia due to
its focus on physical health. Alternative measures need further investigation.
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Background
The impact of caring for people with Alzheimer’s disease
(AD) dementia falls heavily on informal caregivers who
are increasingly required to assist with activities of daily
living (ADL) and make decisions on behalf of patients as
the disease progresses. The health impact on caregivers
can be both physical and emotional [1]; nearly half of the
caregivers in some studies meet formal diagnostic criteria
for depression and show increased use of health services
and psychiatric medication [2]. Caring for a person with
AD dementia can also have a social and financial impact,
and the overall effect on caregivers is thought to be
reflected in deterioration in their health-related quality of
life (HRQoL) as patients become increasingly unable to
care for themselves and perform their usual activities [3].
Thus, HRQoL is a construct that evaluates the impact of
physical and mental disorders and disability on an individ-
ual’s general well-being and can be measured using
generic or disease-specific measures [4].
Caregiver burden is an important multidimensional con-
struct that describes the objective and subjective responses
to the physical, psychological, social and financial demands
* Correspondence: reed_catherine@lilly.com
1Eli Lilly and Company Limited, Erl Wood Manor, Sunninghill Road,
Windlesham, Surrey GU20 6PH, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Reed et al. Health and Quality of Life Outcomes  (2017) 15:16 
DOI 10.1186/s12955-017-0591-2
of caring [5]. Caregiver burden has been associated with
AD dementia severity: caregivers feel more burdened as
AD dementia severity increases [6], although there are
some differences between spousal and adult-child care-
givers in perceived burden measured using the Zarit
Burden Interview (ZBI) [7].
Poorer caregiver HRQoL has not only been associated
with increasing patient dependency [3], but also with
greater caregiver perceived burden and increased time
spent caring [8, 9]. However, two European studies found
poor associations between caregiver and patient HRQoL
[10, 11] as assessed using the EuroQol-5 dimension ques-
tionnaire (EQ-5D), a recognized generic instrument for
measuring HRQoL which elicits a utility value (index
score) [4]. Patient EQ-5D scores decreased with increasing
AD dementia severity, but caregiver EQ-5D scores did not
vary by patient disease severity [10, 11]. These findings
contradict those from other studies (e.g., [3]) and raise the
question of whether caregiver EQ-5D is able to accurately
reflect utility/disutility in AD dementia.
Caregiver time spent on instrumental ADL (T-IADL) is
an alternative measure of caregiver impact that can be
assessed across the full spectrum of disease severity and
contributes to informal care costs when cost-of-illness
studies take a societal perspective [12]. Time spent on basic
ADL such as eating, dressing, and toileting is a less useful
measure of caregiver burden in a community-based AD
dementia population because basic ADL do not usually
become impaired until the moderate-to-severe stages of
AD dementia [13]. Caregiver time increases with increasing
severity of patient AD dementia [6, 14]
Since the results of studies investigating caregiver
HRQoL and burden are inconsistent, further clarification
is needed of the role of caregiver EQ-5D scores in asses-
sing the impact of caring for patients with AD dementia
and the relationship between EQ-5D and alternative
caregiver outcomes. The objective of the present study
was to assess the ability of caregiver EQ-5D to measure
such impact by exploring EQ-5D index scores and their
correlations with ZBI total scores and T-IADL within
the caregiver population in the GERAS study. In particu-
lar, we used longitudinal data to examine change scores
over 18 months and summarized ZBI and T-IADL
change scores by EQ-5D domain change category.
Methods
Study design and participants
GERAS was an 18-month, prospective, multicenter, natur-
alistic, observational cohort study conducted in France,
Germany, and the UK, designed to evaluate the costs and
resource use associated with AD for community-dwelling
patients and their caregivers [12]. The study design, patient
characteristics, and baseline costs and resource-use data
have been reported [12]. The present analysis focuses on
the primary caregivers; baseline characteristics and per-
ceived burden have been reported previously for the overall
caregiver and patient cohorts [6] and by caregiver relation-
ship to the patient (e.g., adult-child, spouse) [7].
Community-dwelling patients (aged ≥55 years) with
probable AD dementia, who presented within the nor-
mal course of care and had a Mini-Mental State Examin-
ation (MMSE) score of ≤26, were enrolled between
October 2010 and September 2011, mostly at specialist
secondary care clinics (memory clinics). Patients were
also required to have a primary caregiver (responsible
for the patient for at least 6 months per year) who was
willing to participate in the study.
The study aimed to recruit equal numbers of people in
each of three disease severity groups based on MMSE
criteria: mild AD dementia (MMSE 21–26 points), moder-
ate AD dementia (MMSE 15–20 points), or moderately
severe/severe (MS/S) AD dementia (MMSE ≤14 points).
Ethical review board approval was obtained in each coun-
try and all participants provided written informed consent
before enrollment.
Data collected
Data were collected for patients and caregivers at the
baseline visit and at 6, 12, and 18 months during routine
care visits. Full details of the baseline patient and caregiver
demographics and characteristics, including comorbidities
and medications used, have been reported previously [12].
Caregiver burden was assessed at every visit using the
22-item version of the original 29-item ZBI [15]. The ZBI
is a self-report inventory where responses to each item are
recorded on a 5-point scale (0 = never to 4 = nearly
always) and used to derive a ZBI total score ranging from
0 to 88, with higher scores indicating greater burden. The
questions focus on the caregiver’s health, psychological
well-being, finances, social life, and relationship with the
patient. The ZBI is a valid, reliable, and widely recognized
measure of subjective caregiver burden [6, 16].
HRQoL was self-assessed by caregivers at the baseline
and 18-month visits using the EQ-5D [17]. Caregivers
scored their current health state in each of five domains
(pain/discomfort, anxiety/depression, mobility, usual activ-
ities, and self-care) using a 3-point scale (1 = no problems,
2 =moderate problems, 3 = extreme problems). From the
health-state profile obtained, a scoring algorithm using
country-specific preference weights [18] was used to calcu-
late a total utility score (EQ-5D index score) between 0
(represents death) and 1.0 (represents perfect health).
Caregivers also rated their current health status on the day
of assessment using the EQ-5D visual analog scale (EQ-5D
VAS), which ranges from 0 (worst imaginable health) to
100 (best imaginable health).
Caregiver time spent looking after the patient was
assessed using the Resource Utilization in Dementia
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(RUD) instrument [19] (version RUD Complete 3.1), by
interview with the caregiver. This is a widely used,
standardized instrument for collecting resource-use data
in dementia and has been validated for use in different
care settings, including in community-dwelling patients
[20, 21]. Time (in the month preceding both the baseline
visit and the 18-month visit) was recorded as the total
number of caregiving hours, including the number of
hours spent on basic ADL (e.g., standard self-care tasks
such as eating, getting dressed), instrumental ADL (e.g.,
cooking, shopping), and patient supervision (i.e., watching
the patient to prevent dangerous events).
Statistical analysis
Baseline characteristics of caregivers and patients were
summarized based on non-missing observations. Data are
presented as means (standard deviations [SDs], medians,
and interquartile range [Q1, Q3]) or as numbers and
percentages of caregivers/patients.
Comparisons between AD dementia severity groups for
caregiver mean EQ-5D, ZBI, and T-IADL used analysis of
variance (ANOVA), with country and baseline MMSE sever-
ity as independent factors. Although these variables do not
follow a normal distribution, the central limit theorem en-
sures the validity of the ANOVA to compare the means,
which are based on a large sample size. Also, because the ef-
fect of country was adjusted for in the ANOVA, it allows the
combination of country-specific derived EQ-5D index scores.
Spearman correlation coefficients examined the within-
subject associations between continuous variables such as
caregiver ZBI total scores, EQ-5D index scores, EQ-5D
VAS scores, and T-IADL, at baseline, at 18 months, and
for the change from baseline to 18 months. We inter-
preted correlation coefficients of 0–0.19 as very weak and
0.20–0.39 as weak.
The change in caregiver ZBI total score or T-IADL over
18 months was examined for the total population accord-
ing to the change in each of the five EQ-5D domains,
which was categorized as better, stable, or worse based on
the numerical changes in each 3-point scale.
All analyses were performed using Statistical Analysis
Software (SAS) version 9.2 (SAS Institute, Cary, NC, USA).
Results
At baseline, the study cohort analyzed comprised 1495
patients with mild AD dementia (n = 566), moderate AD
dementia (n = 472), or MS/S AD dementia (n = 457), and
their caregivers (n = 1495). The number of caregivers and
patients from each country was as follows: France, n =
419; Germany, n = 550; UK, n = 526. A total of 1040
caregivers attended the 18-month visit (69.6%). The main
reasons for discontinuation from the study were patient
institutionalization (n = 214), the patient had died (n = 92),
the caregiver/patient had decided to leave the study (n =
119), or the caregiver/patient was lost to follow-up (n =
26). The number of caregivers with available data at the
18-month visit was: ZBI, n = 932; EQ-5D, n = 934; T-
IADL, n = 983. The number of caregivers with available
data for the change from baseline to 18 months was: ZBI,
n = 931; EQ-5D, n = 933; and T-IADL, n = 982.
Caregiver and patient characteristics
The baseline sociodemographic and clinical characteristics
of the caregivers and patients are summarized in Table 1.
Caregivers had a mean (SD) age of 67.3 (12.0) years and
most were female (64.2%), the spouse of the patient
(65.9%), and living with the patient (76.0%). The majority
of caregivers reported medical conditions (58.6%; mean of
1.1 medical conditions), most commonly hypertension
(36.8%), hypercholesterolemia (23.5%), and depression
(10.1%). Approximately one-quarter of the caregivers
(23.8%) reported working for pay. The patients had a
mean (SD) age of 77.6 (7.7) years, 54.8% were female,
mean (SD) time since diagnosis was 2.2 (2.2) years, and
73.6% had comorbidities (mean of 1.4 comorbidities).
Caregiver HRQoL
The caregivers’ overall mean (SD) EQ-5D index score at
baseline was 0.84 (0.20), and was 0.86 (0.18), 0.85 (0.19),
and 0.82 (0.23) for the mild, moderate, and MS/S AD de-
mentia groups, respectively (ANOVA P = 0.043), indicating
Table 1 Patient and caregiver characteristicsa at baseline
Characteristic Mean (SD) or n (%)
Caregiver, n 1495
Sex, n (%) female 958 (64.2)
Age, mean (SD) 67.3 (12.0)
Relationship to patient, n (%)
Spouse 984 (65.9)
Child 405 (27.1)
Other 104 (6.9)
Lives with patient, n (%) 1135 (76.0)
Working for pay, n (%) 355 (23.8)
Caregivers with medical conditions, n (%) 875 (58.6)
Number of medical conditions, mean (SD) 1.1 (1.2)
Patient, n 1495
Sex, n (%) female 819 (54.8)
Age, mean (SD) 77.6 (7.7)
Time since diagnosis of AD, years, mean (SD) 2.2 (2.2)
MMSE score, mean (SD) 17.4 (6.3)
Patients with comorbidities, n (%) 1101 (73.6)
Number of comorbidities, mean (SD) 1.4 (1.2)
AD Alzheimer’s disease; MMSE Mini-Mental State Examination; SD
standard deviation
aAll data are based on patients/caregivers with non-missing data
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a very slightly lower caregiver HRQoL for patients with
MS/S AD dementia (Table 2). The overall caregiver mean
(SD) EQ-5D VAS score at baseline was 75.1 (17.5), and by
patient AD severity was 75.8 (16.6), 76.3 (16.5), and 72.9
(19.2) for the mild, moderate, and MS/S AD dementia
groups, respectively (ANOVA P = 0.013). The mean (SD)
change from baseline to 18 months was −0.02 (0.21) for the
caregiver EQ-5D index score and −3.0 (18.5) for the
caregiver EQ-5D VAS score. For both caregiver EQ-5D
measures, the change from baseline to 18 months in the
overall sample was not significant and did not differ
significantly across the AD dementia severity groups (data
not shown).
Examination of the EQ-5D domain scores (Fig. 1)
showed that very few caregivers had extreme problems
(<5% for any domain) and the levels of problems were
similar at baseline and at 18 months. At both time points,
more caregivers had some problems in the domains of
pain/discomfort (baseline: 42.8%; 18 months: 46.8%) and
anxiety/depression (baseline: 30.3%; 18 months: 33.9%)
than in the other three domains.
Caregiver burden
ZBI total scores at baseline ranged from 0 to 80 and the
mean (SD) score was 29.0 (15.1). The mean (SD) ZBI total
score showed a greater burden for the patient groups with
worse disease severity: 24.6 (14.2), 29.4 (14.8), and 34.1
(14.8) for the mild, moderate, and MS/S AD dementia
groups, respectively (ANOVA P < 0.001) (Table 2). The
mean (SD) change in ZBI total score from baseline to
18 months was 4.9 (12.6) for the overall cohort of
caregivers, and differed significantly according to patient
disease severity at baseline: 5.4 (11.8), 5.9 (13.7), and 3.0
(12.4) for the mild, moderate, and MS/S AD dementia
groups, respectively (ANOVA P = 0.028).
Caregiver T-IADL
Median caregiver T-IADL during the month before
baseline was 60.0 (Q1, Q3: 20.0, 120.0) hours (Table 2).
This time increased for the patient groups with greater
disease severity and was 36.0 (Q1, Q3: 8.0, 90.0), 60.0 (Q1,
Q3: 24.0, 120.0), and 90.0 (Q1, Q3: 40.0, 120.8) hours for
the month before baseline in the mild, moderate, and MS/
S AD dementia groups, respectively (ANOVA P < 0.001;
see Table 2). The median change from baseline to
18 months in T-IADL was 10.0 (Q1, Q3: −15.0, 45.0)
hours/month for the overall cohort; the median changes
from baseline in the mild, moderate, and MS/S AD
dementia groups were 13.0 (Q1, Q3: −5.0, 52.0), 10.0 (Q1,
Q3: −15.0, 46.5), and 0.0 (Q1, Q3: −30.0, 45.0) hours/
month, respectively (ANOVA P = 0.151).
Table 2 Caregiver HRQoL (EQ-5D) and burden scores at baseline
Measure n Mean (SD) Median (Q1, Q3) P valuea
EQ-5D index scoreb 1483 0.84 (0.20) 0.89 (0.79, 1.00)
Mild AD dementia 560 0.86 (0.18) 0.89 (0.79, 1.00) 0.043
Moderate AD dementia 469 0.85 (0.19) 0.89 (0.79, 1.00)
MS/S AD dementia 454 0.82 (0.23) 0.89 (0.73, 1.00)
EQ-5D VAS scorec 1483 75.1 (17.5) 80.0 (65.0, 90.0)
Mild AD dementia 560 75.8 (16.6) 80.0 (69.0, 89.0) 0.013
Moderate AD dementia 469 76.3 (16.5) 80.0 (69.0, 90.0)
MS/S AD dementia 454 72.9 (19.2) 79.0 (60.0, 89.0)
ZBI total scored 1485 29.0 (15.1) 28.0 (17.0, 40.0)
Mild AD dementia 560 24.6 (14.2) 22.0 (14.0, 33.0) <0.001
Moderate AD dementia 471 29.4 (14.8) 29.0 (18.0, 39.0)
MS/S AD dementia 454 34.1 (14.8) 33.0 (22.0, 45.0)
T-IADL (hours/month) 1493 79.3 (89.5) 60.0 (20.0, 120.0)
Mild AD dementia 565 61.0 (83.1) 36.0 (8.0, 90.0) <0.001
Moderate AD dementia 472 77.5 (79.2) 60.0 (24.0, 120.0)
MS/S AD dementia 456 103.8 (101.1) 90.0 (40.0, 120.8)
AD Alzheimer’s disease; EQ-5D EuroQol-5 dimension questionnaire; HRQoL health-related quality of life; MS/S moderately severe/severe; Q1, Q3 interquartile range;
SD standard deviation; T-IADL time spent on instrumental activities of daily living; VAS visual analog scale; ZBI Zarit Burden Interview
Missing data (overall): EQ-5D, n = 12; ZBI, n = 10; T-IADL, n = 2
aComparisons between AD severity groups used analysis of variance (ANOVA) with country and baseline Mini-Mental State Examination (MMSE) severity as
independent factors
bCountry-specific health status index score; range 0 to 1.0, higher scores indicate better health-related quality of life
cEQ-5D VAS score range = 0–100, higher scores indicate better health-related quality of life
dZBI total score range = 0–88, higher scores indicate greater burden
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Correlations Between EQ-5D, ZBI, and T-IADL
Correlations were weak or very weak between EQ-5D
(index and VAS scores) and ZBI or T-IADL at each
time point and for the change scores (Table 3). For
the ZBI, the 18-month change score correlation was −0.16
(95% confidence interval, CI: −0.22, −0.09) for the EQ-5D
VAS score and −0.09 (95% CI: −0.15, −0.03) for the EQ-
5D index score. Caregiver T-IADL showed weak correl-
ation with ZBI scores, and the 18-month change score
correlation was 0.12 (95% CI: 0.05, 0.18). However,
there was no significant correlation between the 18-
month change scores for T-IADL and the EQ-5D
index score (Table 3).
ZBI Scores by EQ-5D Domain
The mean ZBI total scores at baseline and at 18 months by
EQ-5D domain showed that burden tended to be greater
(higher mean ZBI total score) among caregivers with greater
problem severity in each EQ-5D domain (data not shown).
From baseline to 18 months, the HRQoL of the majority of
caregivers (68–90%) was stable in each EQ-5D domain,
though some caregivers (3–14%) showed better EQ-5D
scores in some domains than at baseline. HRQoL worsened
from baseline to 18 months in 7% of caregivers within the
self-care domain, 10% within the mobility domain, 13% in
the usual activities domain, 17% in anxiety/depression
domain, and 18% in the pain/discomfort domain (Fig. 2).
Fig. 1 Problems in caregiver EQ-5D domains at baseline and 18 months. Baseline: n = 1483 (data missing for 12 caregivers); 18 months: n = 934
(data missing for 113 caregivers). EQ-5D, EuroQol-5 dimension questionnaire
Table 3 Correlationsa between caregiver EQ-5D, T-IADL, and ZBI scores
Variable Time point EQ-5D VAS score EQ-5D index score T-IADL
n Coefficient 95% CI P value n Coefficient 95% CI P value n Coefficient 95% CI P value
ZBI total
score
Baseline
vs baseline
1483 −0.21 −0.26, −0.16 <0.001 1483 −0.21 −0.25, −0.16 <0.001 1484 0.30 0.25, 0.34 <0.001
18 months
vs 18 months
929 −0.19 −0.26, −0.13 <0.001 929 −0.21 −0.27, −0.15 <0.001 928 0.22 0.15, 0.28 <0.001
Change score
vs change scoreb
928 −0.16 −0.22, −0.09 <0.001 928 −0.09 −0.15, −0.03 0.006 926 0.12 0.05, 0.18 <0.001
T-IADL Baseline vs
baseline
1482 −0.15 −0.19, −0.10 <0.001 1482 −0.14 −0.19, −0.09 <0.001
18 months vs
18 months
930 −0.08 −0.15, −0.02 0.010 930 −0.10 −0.16, −0.03 0.004
Change score vs
change scoreb
928 −0.07 −0.13, −0.01 0.030 928 0.02 −0.04, 0.08 0.546
CI confidence interval; EQ-5D EuroQol-5 dimension questionnaire; T-IADL time spent on instrumental activities of daily living (hours/month); VAS visual analog
scale; ZBI Zarit Burden Interview
aSpearman correlation coefficients, 95% CIs, and P values
bChange in score from baseline to 18 months
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As evidenced by Fig. 2, which shows the mean change
in ZBI total score by EQ-5D domain change category
over 18 months, there was a trend for caregivers who
experienced a worsening in EQ-5D domain score over
18 months to have the largest increases in ZBI total
score (i.e., the greatest increase in caregiver burden).
T-IADL by EQ-5D Domain
Figure 3 summarizes the median change in caregiver T-
IADL by EQ-5D domain change category over 18 months.
Of the 982 caregivers with available data on the change in T-
IADL, the EQ-5D domain change category was missing for
54 (5%). Fig. 3 shows that there was no clear pattern for me-
dian change in T-IADL by EQ-5D domain change category.
Discussion
The impact of AD dementia on caregivers is substantial
and should be considered when evaluating the societal im-
pact of this disease. Although caregiver outcomes are not
typically included in economic evaluations, a preference-
based measure such as the EQ-5D can be used to inform
economic evaluations [7, 22]. However, the results of our
analysis suggest that the EQ-5D is not particularly effect-
ive for capturing the true impact on caregivers of caring
for people with AD dementia: the EQ-5D index score had
a low sensitivity to change over an 18-month period and
was not clearly differentiated by patient AD dementia se-
verity. EQ-5D index and VAS scores had weak or very
weak correlations with other potential measures of impact,
perceived caregiver burden (ZBI) and a measure of care-
giver time (caregiver T-IADL), both assessed using stan-
dardized instruments.
When the EQ-5D was analyzed at the domain level, care-
givers who experienced a worsening in HRQoL domain
score over 18 months had a greater increase in mean ZBI
total score than caregivers whose HRQoL domain score
remained stable or improved. However, this trend was not
observed when the EQ-5D domains were combined into
the single EQ-5D index score (Table 3 shows a very weak
correlation between the change scores).
The longitudinal GERAS study included a large sample
of community-dwelling patients with a wide range of
AD dementia severity who participated with their care-
givers, with assessments being made in a naturalistic set-
ting. The caregivers participating in the GERAS study had
a high mean EQ-5D index score (0.84) at baseline, show-
ing that they had relatively good HRQoL, similar to that
of the general population of people aged 65–74 years in
each country (France: 0.81; Germany: 0.89; and UK: 0.78
from Table 3.6 in Szende et al. [18]). The EQ-5D index
score from our study is also consistent with a previous
study showing little difference in utility values in a UK
general population sample (n = 77) and caregivers of
people with mild dementia (n = 71), where the mean (SD)
EQ-5D scores were 0.79 (0.25) for the general population
sample and 0.78 (0.19) for the caregivers [23]. However,
these caregivers of people with dementia gave lower utility
values for dementia health states than members of the
general population; this could impact on the results of
cost–utility analyses, which generally use general popula-
tion values [23].
There were minimal changes in caregiver EQ-5D scores
over the 18-month follow-up period. However, as the EQ-
5D is a brief generic measure of health status rather than an
AD-specific HRQoL scale, it may miss both disease-specific
and caregiver-specific impacts [4]. The majority of caregivers
reported no problems in the EQ-5D domains of mobility,
self-care, and usual activities, which reflect physical health,
Fig. 2 Change in caregiver ZBI total score by EQ-5D domain change category from baseline to 18 months (n = 931). Change in EQ-5D domain
data were missing for three of these caregivers. EQ-5D, EuroQol-5 dimension questionnaire; ZBI, Zarit Burden Interview
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implying that these caregivers generally had the good
physical health to be able to perform their role as caregiver.
Approximately half of the caregivers reported some or ex-
treme problems in the pain/discomfort domain and about
one-third of caregivers had some or extreme problems in
the anxiety/depression domain, reflecting emotional/mental
health. This is consistent with previous reports that a high
proportion of informal caregivers of patients with AD de-
mentia report problems in the EQ-5D domains of pain/dis-
comfort and anxiety/depression [3, 9]. As the GERAS study
required caregivers to be the established caregiver, the im-
pact on pain/discomfort and anxiety/depression scores may
have been captured at baseline with low caregiver expect-
ation of much change over time. These findings suggest that,
because some of the EQ-5D domains are at ceiling scores
(with few caregivers remaining in the study expected to
decline much in the physical or emotional domains),
caregiver EQ-5D is not a particularly informative or sensitive
measure of the impact of caring for patients with AD de-
mentia. It is possible that most caregivers who remained in
the study were physically healthy and that patients discon-
tinuing the study (for reasons including institutionalization
or death) were those experiencing more acute problems.
The discontinuation of caregivers of these patients may
thereby reduce the likelihood of observing caregivers with
extreme problems.
In our study, the increase in ZBI total score over time dif-
fered according to patient AD dementia severity at baseline
and was highest for those caring for patients with moderate
AD dementia and lowest for caregivers of patients with
MS/S AD dementia. The greatest change in caregiver bur-
den may be expected to occur in moderate AD dementia
because patients often develop more behavioral problems
during this stage of the disease; we believe that by the time
the patient has progressed to more severe AD dementia,
caregivers are likely to have adapted their life and reached a
peak in their perceived burden, and patients may be receiv-
ing more formal care. There was a tendency for the in-
crease in mean ZBI total score to be greatest among
caregivers who showed a worsening in each of the EQ-5D
domains, especially the anxiety/depression domain.
Little published information exists on the relationship
between caregiver burden and HRQoL over time in
dementia. However, our finding that EQ-5D is a relatively
insensitive measure of the impact of caring is consistent
with a previous longitudinal study where the mean ZBI
score was higher for caregivers of home-living patients
with dementia (32.4) than for caregivers of patients with
dementia in long-term care (24.9), while the mean EQ-5D
index score was similar for both types of caregiver (0.76
and 0.78, respectively) [24]. Furthermore, for a subgroup
of caregivers where the patient transitioned from home to
institutional care during the 3-month follow-up period,
the mean ZBI score decreased from 35.4 to 22.4, while the
caregiver EQ-5D index score remained stable at 0.77 [24].
Caregiver T-IADL is sensitive to change across the full
range of AD dementia severity and is a common out-
come measure in clinical trials. Our analyses showed
that caregiver T-IADL had very weak correlations with
caregiver EQ-5D scores (index and VAS scores), and that
there was no clear pattern for the change in caregiver T-
IADL by change in EQ-5D domains, reinforcing our
conclusion that EQ-5D is not a sensitive measure of the
impact of caring for people with AD dementia.
The relationship between caregiver HRQoL and T-IADL
needs further investigation. A recent systematic review on
Fig. 3 Change in caregiver T-IADL by EQ-5D domain change category from baseline to 18 months (n = 982). Change in EQ-5D domain data were
missing for 54 of these caregivers. 95% confidence intervals are bootstrap-based. EQ-5D, EuroQol-5 dimension questionnaire; T-IADL, time spent
on instrumental activities of daily living (hours/month)
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the relationship between caregiver quality of life (QoL, cov-
ering the broader concept of complete physical, mental,
and social well-being) and the level/quality of care provided
to people with AD included only one study, QoL was mea-
sured as overall well-being using the Perceived Change
Index, and the evidence was equivocal [25]. An increase in
caregiver QoL over six months was associated with an in-
crease in T-IADL, although there was a decrease in total
caregiving hours [25]. This suggests that caregivers with a
better HRQoL are able to spend more time addressing spe-
cific aspects of care related to instrumental ADL, such as
housework, financial management, and correct use of med-
ications. Thus, we can speculate that interventions which
improve caregiver HRQoL may improve the level of care
that caregivers provide to people with AD dementia.
Taken together, our results imply that the EQ-5D may
not be the most appropriate measure of the impact of
caring for people with AD dementia given the structure
of its domains. This suggests that, although the EQ-5D
is commonly used in health economics and outcomes
research involving caregivers of people with dementia
[26], it may not be sensitive enough to measure changes
in caregiver HRQoL. Thus, the EQ-5D may underesti-
mate the impact of an intervention on the caregiver and,
therefore, its cost-effectiveness.
Other instruments have been developed that measure
the impact of caregiving on informal caregivers, which can
be used in economic evaluations; these include the Care-
related Quality of Life instrument (CarerQoL) [27, 28] and
the Caregiver Experience Scale (CES) [29, 30]. However,
these instruments are still undergoing validation.
There are several limitations to our study. First, the
GERAS study included only community-dwelling patients
at enrollment who had primary caregivers willing to partici-
pate in the study. Thus, our sample of caregivers may not
be representative of all caregivers for AD, as it includes only
those able/willing to participate. This is reflected in the high
proportion of caregivers who had no problems in the EQ-
5D domains of mobility, self-care, and usual activities,
although we were able to examine changes in EQ-5D over
time. Second, as HRQoL (measured using EQ-5D) is a
different construct from caregiver burden and time spent
on ADL, this has imposed some limitation on our analysis.
However, our aim was to understand how these commonly
reported measures improve our understanding of the im-
pact of AD for the caregiver and enhance understanding of
how the measures best align with the decline in patients’
AD severity. Third, other factors that may influence
caregiver HRQoL, burden and time spent caring, such as
depression in the caregiver or neuropsychiatric symptoms
in the person with AD dementia [2, 6, 31, 32], were not in-
cluded within the current objective of our analyses. Fourth,
our analysis is based only on those caregivers with available
data at 18 months, and evaluated score data at baseline and
18 months only. In addition, we used pooled data from
three countries and it would be interesting to examine
whether there are country-level effects. As part of our
descriptive summary of longitudinal GERAS study results,
we investigated the EQ-5D index scores from all countries
based on the UK population values and have seen little
difference from those generated using country-specific
values (data available on request). We found no evidence to
suggest that the relationship between EQ-5D and the other
measures would differ by country. Fifth, changes in ZBI
and T-IADL cannot be compared in the same way as EQ-
5D domain changes, as they are continuous scores. Assess-
ment of T-IADL by the caregiver may be subject to recall
bias although an electronic diary to record time spent
giving care was provided for the purposes of this study.
Finally, caregiver HRQoL and burden may change after the
patient with AD dementia has been institutionalized
[33, 34]. We will report caregiver EQ-5D and ZBI after pa-
tient institutionalization or death in a future publication.
Conclusions
Our findings indicate that EQ-5D may not be the best meas-
ure of the impact on caregivers of caring for people with AD
dementia because it mainly focuses on physical health. Alter-
native measures, including measures of caregiver burden
assessed using the ZBI or caregiver time, may provide a more
accurate picture of the impact of caring for a person with
AD dementia, and require further investigation. This
approach of assessing caregiver burden is perhaps more rele-
vant than looking at HRQoL, as the current emphasis is on
developing interventions aimed at relieving caregiver burden.
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